P-LAP/IRAP-induced cell proliferation and glucose uptake in endometrial carcinoma cells via insulin receptor signaling
© Shibata et al; licensee BioMed Central Ltd. 2007
Received: 04 August 2006
Accepted: 19 January 2007
Published: 19 January 2007
Hyperglycemia or hyperinsulinemia contributes to poorer endometrial cancer survival. It was shown that P-LAP/IRAP translocates to the plasma membrane in response to insulin stimulation. Recently, we demonstrated that P-LAP/IRAP is associated with a poor prognosis in endometrial adenocarcinoma patients. The aim of this study was to examine whether the malignant potential of endometrial cancer enhanced by P-LAP/IRAP is due to increased glucose uptake via the P-LAP/IRAP-mediated activation of insulin signaling.
We transfected P-LAP/IRAP cDNA into A-MEC cells (endometrial adenocarcinoma cell line), and A-MEC-LAP cells expressed a remarkably high level of GLUT4 proteins.
3H-2-deoxyglucose uptake which responds to insulin in A-MEC-LAP cells was significantly higher than that of A-MEC-pc cells. A-MEC-LAP cells exhibited a significant growth-stimulatory effect compared to A-MEC-pc cells. A-MEC-LAP cells expressed a remarkably high level of p85PI3K protein compared to A-MEC-pc cells, and showed a higher degree of AKT phosphorylation by insulin stimulation.
In summary, P-LAP/IRAP was involved in the increasing malignant potential of endometrial cancer mediated by insulin. P-LAP/IRAP was suggested to be a potential new target of molecular-targeted therapy for endometrial cancer.
Endometrial carcinoma is the most common gynecological malignancy in the United States. Recently, the incidence of this disease has been increasing in Japan. Several personal and lifestyle-related characteristics, such as age, obesity, diabetes, and estrogen therapy, have been identified as risk factors for developing endometrial cancer . A recent study showed that diabetes is associated with reduced survival after endometrial cancer, independent of tumor stage and grade . This finding suggested the possibility of a diabetes-related condition, such as hyperglycemia or hyperinsulinemia, contributing to reduced survival in endometrial cancer patients. Furthermore, an in vitro study showed that endometrial cancer cells have high-affinity binding sites for insulin and proliferate in response to insulin exposure . Several studies have shown that insulin signal transduction proteins, in particular the insulin receptor (IR) and IRS-1, may also contribute to the development of various tumors [4, 5].
Placental leucine aminopeptidase (P-LAP) is a cell surface aminopeptidase, and is a synonym for oxytocinase . P-LAP is also referred to as insulin-regulated membrane aminopeptidase (IRAP), associated with the glucose transporter 4 (GLUT4) containing vesicle [7–9]. It was shown that P-LAP/IRAP translocates to the plasma membrane in response to insulin stimulation. Recently, we demonstrated that P-LAP/IRAP is present in both human endometrial adenocarcinoma tissues and cells, and that it acts as a regulator of carcinoma cell growth . Furthermore, we demonstrated that P-LAP/IRAP is associated with a poor prognosis in human endometrial adenocarcinoma patients . The aim of this study was to examine whether the proliferation of endometrial cancer enhanced by P-LAP/IRAP is due to increased glucose uptake via the P-LAP/IRAP-mediated activation of insulin signaling.
Tissue specimens were obtained from patients who were surgically treated at Nagoya University Hospital. All tissue samples were fixed in 10% formalin, embedded in paraffin, and routinely stained with hematoxylin and eosin for histological examination. Endometrial adenocarcinomas were graded according to the criteria of the World Health Organization and classified as grade 1 (well-differentiated), grade 2 (moderately- differentiated), or grade 3 (poorly-differentiated). The relevant institutional review boards approved the study and informed consent from which all patients signed.
Cell lines and culture conditions
We used 3 human endometrial endometrioid adenocarcinoma cell lines (A-MEC, HEC1A, and Ishikawa). A-MEC was a kind gift from Aichi Medical University, Ishikawa from Dr. M. Nishida (Kasumigaura Hospital, Ibaragi, Japan), and HEC1A from Professor H. Kuramoto (Kitazato University, Kanagawa, Japan). Cells were maintained in RPMI 1640 medium (Sigma Chemical Co., St. Louis, MO) supplemented with 10% fetal calf serum (FCS) and penicillin-streptomycin. These cells were incubated at 37 C in a humidified atmosphere of 5% CO2.
Immunohistochemical staining was performed using the avidin-biotin immunoperoxidase technique (Histofine SAB-PO kit, Nichirei, Tokyo, Japan). Sections were cut at a thickness of 4 μm, and immunostained by the streptavidin/biotin/peroxidase method. Deparaffinized sections in 0.01 M citrate buffer were treated three times for 5 min each at 90 C and 750 W using an H2500 microwave oven. Sections were incubated in 0.3 % hydrogen peroxide for 20 min and then further incubated with 10 % normal goat serum for 10 min to block the endogenous peroxidase activity and non-specific immunoglobulin binding, respectively. Rabbit polyclonal antibody (sc-710, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) at a 1:100 dilution was used for insulin receptor (IR) a, rabbit polyclonal antibody (Upstate, Inc., Lake Placid, NY) at 1:200 dilution was used for insulin receptor substrate-1 (IRS-1), rabbit polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) at a 1:50 dilution was used for GLUT4, and rabbit polyclonal antibody at 1: 100 was used for P-LAP/IRAP. They were added to the tissue sections and incubated for 1 h in a moist chamber at room temperature. Binding of the antibodies was followed with biotinylated goat anti-rabbit IgG and horse-radish peroxidase-conjugated streptavidin (Histofine SAB-PO, Nichirei). Chromogenic development was performed by immersion of the sections in 3-amino-9-ethylcarbazole (AEC, Nichirei). The slides were counterstained with Mayer's hematoxylin.
Plasmid construction and transfection
The eukariotic expression vector pcDNA3.1(-) (Invitrogen Japan K.K., Tokyo, Japan) was used to drive the expression of inserted P-LAP/IRAP cDNA. Transfections were carried out using Lipofectamine according to the manufacturer's instructions (Invitrogen Japan K.K., Tokyo, Japan). A-MEC cells were transfected with pcDNA3.1(-) (A-MEC-pc) or pcDNA3.1(-) inserted with P-LAP/IRAP cDNA (A-MEC-LAP). Stable transfectants were selected by growth in medium supplemented with 400 mg/ml of G418 (Sigma Chemical Co., St. Louis, MO). Several hundred clones resistant to G418 were obtained and polyclonal cells from these transfectants were used in the following experiments to eliminate any effects that could be attributed to clonal variation.
Cell lysates were electrophoresed on 7.5% sodium dodecyl sulfate polyacrylamide gel under reducing conditions. After electrophoresis, the proteins were transferred electrophoretically to an Immobilon membrane (Millipore, Bedford, MA, USA). After blocking, the membrane was incubated for 1 h with rabbit polyclonal antibody against human P-LAP/IRAP, GLUT4, insulin receptor, IRS-1, p-Ser307-IRS1 (Upstate Biotechnology, Lake Placid, NY), p-Tyr1158-IR(Abcam, Cambrige, UK), and mouse monoclonal antibody for phospho-AKT (587F11, Cell Signaling Technology, Inc.) and p85 PI-3 kinase (sc-1637, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) The membrane was washed with TBS-T for 15 min three times, and then incubated with peroxidase-conjugated goat anti-rabbit IgG for 1 h. After washing with TBS-T, the membrane was subjected to ECL-Western blotting detecting reagent (Amersham Biosciences K.K., Tokyo, Japan).
Cellular glucose uptake in P-LAP/IRAP transfection cells
A-MEC-pc and A-MEC-LAP cells were cultured in 12-well plates. Twenty-four h after plating, the cells were serum-starved for 2 h, then incubated in either the presence or absence of 10 nM insulin for 20 min, followed by the addition of 2-deoxy-D-2,6-3H-glucose to a final concentration of 1 μCi/ml. Insulin was purchased from Sigma (Japan).
Cell growth analysis
To evaluate the effect of insulin on cell proliferation, cells were seeded in triplicate in 96-well plates at a density of 5000 cells in a volume of 200 ml. Twenty-four h after plating, insulin was added to the culture medium at concentrations ranging from 10-8 to 10-7 M in the presence 5% FCS. Cell viability after 48 h was assayed using a modified tetrazolium salt 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay with the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay kit (Promega Corp., Tokyo, Japan) according to the manufacturer's instructions. Absorbance was measured at 490 nm by a microplate reader (Multiskan Bichromatic, Labsystems, Helsinki, Finland).
Statistical comparisons among groups were performed using Student's t-test and ANOVA with Bonferroni corrections. Differences between groups were considered significant at p < 0.05.
Expressions of P-LAP/IRAP, GLUT4, IR, and IRS-1 in endometrial carcinoma tissues and cell lines
Involvement of P-LAP/IRAP in glucose uptake in endometrial carcinoma cells
Involvement of P-LAP/IRAP in insulin-induced cell growth
The effect of P-LAP/IRAP transfection on insulin induced activation of the PI3K/AKT pathway in A-MEC cells
Blockade of the PI3K/Akt pathway inhibited the effect of insulin on A-MEC-LAP cell
Tumorigenesis is associated with enhanced cellular glucose uptake and increased metabolism. Indeed, both GLUT1 and GLUT4 are aberrantly expressed in many tumors; for example, overexpression of GLUT1 is found in breast, thyroid, gastric, and liver cancer [10–13]. GLUT4 is expressed in human astrocytic tumors, a subset of lung cancers, gastric cancer, and rhabdomyosarcoma [14–17]. Furthermore, a recent study showed that the tumor suppressor p53 down regulates GLUT1 and GLUT4 gene expression . In previous studies, we demonstrated that P-LAP/IRAP was a poor prognostic factor of endometrial cancer, and that P-LAP/IRAP was involved in proliferation, anticancer agent resistance, and anti-apoptosis by a P-LAP/IRAP gene transfer experiment [11, 12, 19]. In this study, we showed the tendency of an increased GLUT4 immunoreactivity with the advancement of the tumor grade, and this tendency was similar to the results of P-LAP/IRAP. Diabetes and hyperglycemia are poor prognostic factors of endometrial cancer, and in vitro insulin responsiveness and enhanced proliferation of endometrial cancer cells have also been reported [1, 2, 13, 14, 20, 21]. P-LAP/IRAP resides in GLUT4 vesicles, and is known to migrate to the cell membrane to facilitate glucose uptake into cells in response to insulin stimulation. In this study, we first demonstrated that P-LAP/IRAP gene transfer increased GLUT4 expression in endometrial cancer cell lines, with resulting increases in glucose uptake into cells and the cell proliferation capacity in response to insulin. Also, increased PI3K-AKT signal expression, a representative one in insulin signaling, was noted in the P-LAP/IRAP gene-transferred cells. The above results suggest the involvement of P-LAP/IRAP expression in insulin-induced carcinogenesis and a higher degree of malignancy of endometrial cancer cells. Recently, there have been several reports concerning activated AKT signal involvement in anticancer agent resistance [22–24]. We also reported the involvement of P-LAP/IRAP in anticancer agent resistance and anti-apoptosis. These results suggest that P-LAP/IRAP may also be involved in anticancer agent resistance via the activation of insulin signaling. We had postulated the involvement of enzyme activity in many cases of P-LAP/IRAP-induced increased proliferation and the anticancer agent resistance of endometrial cancer cells, and, in this study, we demonstrated the possibility that an increased glucose uptake into the cells by insulin also induces cell proliferation in endometrial cancer cells. Further studies on the mechanism of increased GLUT4 expression by P-LAP/IRAP gene transfer are needed in the future. In this regard, the involvement of hormonal treatment (e.g., estrogen and progesterone) and p53 in the regulation of GLUT4 expression has been reported [18, 25], and their implications in P-LAP/IRAP expression must therefore be investigated.
In summary, P-LAP/IRAP was involved in the progression of endometrial cancer mediated by insulin signaling. P-LAP/IRAP was suggested to be a potential new target of molecular-targeted therapy for endometrial cancer.
This work demonstrated that P-LAP/IRAP is involved in the increasing malignant potential of endometrial cancer mediated by insulin and to be a potential new target of molecular-targeted therapy for endometrial cancer.
This work was supported in part by Grants-in-Aid from the Ministry of Posts, Telecommunications of Japan for specific medical research (collaboration with Nagoya Teishin Hospital).
- Rose PG: Endometrial carcinoma. N Engl J Med. 1996, 335: 640-649. 10.1056/NEJM199608293350907.View ArticlePubMedGoogle Scholar
- Folsom AR, Anderson KE, Sweeney C, Jacobs DR: Diabetes as a risk factor for death following endometrial cancer. Gynecologic Oncology. 2004, 94: 740-745. 10.1016/j.ygyno.2004.06.027.View ArticlePubMedGoogle Scholar
- Nagamani M, Stuart CA: Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol. 1998, 179: 6-12. 10.1016/S0002-9378(98)70244-3.View ArticlePubMedGoogle Scholar
- Papa V, Belfiore A: Insulin receptors in breast cancer: biological and clinical role. J Endocrinol Invest. 1996, 19: 324-333.View ArticlePubMedGoogle Scholar
- Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC, Conover CA: Functional insulin receptors on human epithelial ovarian carcinoma cells: Implications for IGF-II mitogenic signaling. Endocrinology. 2002, 143: 3259-3267. 10.1210/en.2001-211408.View ArticlePubMedGoogle Scholar
- Tsujimoto M, Mizutani S, Adachi H, Kimura M, Nakazato H, Tomoda Y: Identification of human placental leucine aminopeptidase as oxytocinase. Arch Biochem Biophys. 1992, 292: 388-392. 10.1016/0003-9861(92)90007-J.View ArticlePubMedGoogle Scholar
- Keller SR, Scott HM, Mastick CC, Aebersold R, Lienhard GE: Cloning and characterization of a novel insulin-regulated membrane aminopeptidase from Glut4 vesicles. J Biol Chem. 1995, 270: 23612-23618. 10.1074/jbc.270.35.20497.View ArticlePubMedGoogle Scholar
- Carvalho E, Schellhorn SE, Zabolotny JM, Martin S, Tozzo E, Peroni OD, Houseknecht KL, Mundt A, James DE, Kahn BB: GLUT4 overexpression or deficiency in adipoctes of transgenic mice alters the composition of GLUT4 vesicles and the subcellular localization of GLUT4 and IRAP. J Biol Chem. 2004, 279 (20): 21598-21605. 10.1074/jbc.M312269200.View ArticlePubMedGoogle Scholar
- Thoidis G, Kandror KV: A GLUT4-vesicle marker protein, insulin-responsive aminopeptidase is localized in a novel vesicular compartment in PC12 cells. Traffic. 2001, 2: 577-587. 10.1034/j.1600-0854.2001.20807.x.View ArticlePubMedGoogle Scholar
- Suzuki Y, Shibata K, Kikkawa F, Kajiyama H, Ino K, Nomura S, Tsujimoto M, Mizutani S: Possible role of placental leucine aminopeptidase (P-LAP) in the antiproliferative effect of oxytocin in human endometrial adenocarcinoma. Clin Cancer Res. 2003, 9 (4): 1528-1534.PubMedGoogle Scholar
- Shibata K, Kikkawa F, Suzuki Y, Mizokami Y, Kajiyama H, Ino K, Nomura S, Nagasaka T, Mizutani S: Expression of placental leucine aminopeptidase is associated with a poor outcome in endometrial endometrioid adenocarcinoma. Oncology. 2004, 66 (4): 288-295. 10.1159/000078329.View ArticlePubMedGoogle Scholar
- Kondo C, Shibata K, Terauchi M, Kajiyama H, Ino K, Nomura S, Nawa A, Mizutani S, Kikkawa F: A novel role for placental leucine aminopeptidase (P-LAP) as a determinant of chemoresistance in endometrial carcinoma cells. Int J Cancer. 2006, 118 (6): 1390-1394. 10.1002/ijc.21509.View ArticlePubMedGoogle Scholar
- Anderson KE, Anderson E, Mink PJ, Hong CP, Kushi LH, Sellers TA, Lazovich D, Folsonm AR: Diabetes and endometrial cancer in the IowaWomen's Health Study. Cancer Epidemiol Biomarkers Prev. 2001, 10: 611-616.PubMedGoogle Scholar
- Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami HO: Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer. 1997, 71: 360-363. 10.1002/(SICI)1097-0215(19970502)71:3<360::AID-IJC9>3.0.CO;2-W.View ArticlePubMedGoogle Scholar
- Ito T, Noguchi Y, Satoh S, Hayashi H, Inayama Y, Kitamura H: Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol. 1998, 11: 437-443.PubMedGoogle Scholar
- Noguchi Y, Marat D, Saito A, Yoshikawa T, Doi C, Fukuzawa K, Tsuburaya A, Satoh S, Ito T: Expression of facilitative glucose transporters in gastric tumors. Hepatogastroenterology. 1999, 46: 2683-2689.PubMedGoogle Scholar
- Armoni M, Quon MJ, Maor G, Avigad S, Shapiro DN, Harel C, Esposito D, Goshen Y, Yaniv I, Karnieli E: PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro. J Clin Endocrinol Metab. 2002, 87: 5312-5324. 10.1210/jc.2002-020318.View ArticlePubMedGoogle Scholar
- Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E: The tumor suppressor p53 down-regulates glucose transporter GLUT1 and GLUT4 gene expression. Cancer Res. 2004, 64: 2627-2633. 10.1158/0008-5472.CAN-03-0846.View ArticlePubMedGoogle Scholar
- Shibata K, Kikkawa F, Kondo C, Mizokami Y, Kajiyama H, Ino K, Nomura S, Mizutani S: Placental leucine aminopeptidase (P-LAP) expression is associated with chemosensitivity in human endometrial carcinoma. Gynecol Oncol. 2004, 95 (2): 307-313. 10.1016/j.ygyno.2004.07.054.View ArticlePubMedGoogle Scholar
- Troisi R, Potischman N, Hoover RN, Siiteri P, Brinton LA: Insulin and endometrial cancer. Am J Epidemiol. 1997, 146 (6): 476-482.View ArticlePubMedGoogle Scholar
- Berstein LM, Kvatchevskaya JO, Poroshina TE, Kovakenko IG, Tsyrlina EV, Zimarina TS, Oumantcheeva AF, Ashrafian L, Thijssen JH: Insulin resistance, its consequences for clinical course of the disease and possibilities of correction in endometrial cancer. J Cancer Res Clin Oncol. 2004, 130 (11): 687-693. 10.1007/s00432-004-0587-2.View ArticlePubMedGoogle Scholar
- Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E: AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol. 2004, 94 (3): 785-795. 10.1016/j.ygyno.2004.06.023.View ArticlePubMedGoogle Scholar
- Grandage VL, Gale RE, Linch DC, Khwaja A: PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Luekemia. 2005, 19 (4): 586-594.Google Scholar
- Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Maehara Y: Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer. 2005, 117 (3): 376-380. 10.1002/ijc.21170.View ArticlePubMedGoogle Scholar
- Medina RA, Meneses AM, Vera JC, Guzman C, Nualant F, Astuya A, Garcia LA, Kato S, Carvajal A, Pinto M, Owen GI: Estrogen and progesteroneup-regulate glucose transporter expression in ZR-75-1 human breast cancer cells. Endocrinology. 2003, 144: 4527-4535. 10.1210/en.2003-0294.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/7/15/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.